StreetInsider.com News Articles

Veracyte wins Medicare coverage for Prosigna breast cancer test

Fri, 16 Oct 2026 09:15:44 -0400

Veracyte, Inc. (Nasdaq: VCYT) announced that its Prosigna Breast Risk of Recurrence test has received coverage through Palmetto GBA's MolDX program, establishing a Medicare reimbursement path for eligible early-stage breast cancer patients.

Coverage took effect August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive breast cancer who meet Medicare criteria, including stage I or II disease with zero to three positive lymph nodes, according to the company's statement.

The reimbursement decision follows Prosigna's U.S. launch in June 2026. The test analyzes tumor biology to estimate the likelihood of breast cancer recurrence over 10 years, combining molecular data with

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Fri, 16 Oct 2026 09:15:00 -0400

Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer

SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna® Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA’s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment.

Following Prosigna’s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Fri, 16 Oct 2026 09:15:00 -0400

Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer

Following Prosigna’s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

Wed, 14 Oct 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/kgcmbvpd.

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

Wed, 14 Oct 2026 16:05:00 -0400

The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/kgcmbvpd.

Veracyte's Decipher test predicts hormone therapy benefit in prostate cancer

Tue, 29 Sep 2026 08:08:28 -0400

Veracyte, Inc. (Nasdaq: VCYT) announced findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial, showing that its Decipher Prostate Genomic Classifier can predict which intermediate-risk prostate cancer patients are more likely to benefit from adding short-term androgen deprivation therapy (ADT) to dose-escalated radiation.

The results were presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting in Boston by Angela Jia, M.D., Ph.D., of University Hospitals Seidman Cancer Center and Case Western Reserve University.

The analysis examined tumor samples from 395 patients enrolled in the trial, with a median follow-up of 10.2 years. Patients with

Veracyte's Decipher test predicts hormone therapy benefit in prostate cancer

Tue, 29 Sep 2026 08:08:28 -0400

The analysis examined tumor samples from 395 patients enrolled in the trial, with a median follow-up of 10.2 years. Patients with

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Tue, 29 Sep 2026 08:00:00 -0400

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The trial evaluated dose-escalated radiation with or without short-term androgen deprivation therapy (ADT) in men with intermediate-risk prostate cancer. The analysis showed that the

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Tue, 29 Sep 2026 08:00:00 -0400

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Fri, 25 Sep 2026 17:12:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that eight studies leveraging its Decipher Prostate Genomic Classifier test and whole-transcriptome data will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting. The conference will take place September 26–30 in Boston.

The presentations include analyses from Phase II and III clinical trials, Genomic Research for Intelligent Discovery (GRID) research, and national real-world studies. Together, they examine Decipher’s prognostic value in assessing disease risk and predictive value in identifying which patients may

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Fri, 25 Sep 2026 17:12:00 -0400

Form 144 VERACYTE, INC. Filed by: Holstein Jens

Thu, 24 Sep 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260924/27102506.html

Form 4 VERACYTE, INC. For: Sep 21 Filed by: Leite John

Tue, 22 Sep 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260922/27091897.html

Form 8-K VERACYTE, INC. For: Sep 10

Tue, 22 Sep 2026 17:10:00 -0400

si-local-file:///var/storage/secattach/20260922/27091813.html

Form 144 VERACYTE, INC. Filed by: Leite John

Mon, 21 Sep 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260921/27085722.html

Form 4 VERACYTE, INC. For: Sep 14 Filed by: Holstein Jens

Wed, 16 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260916/27070339.html

Needham Reiterates Buy Rating on Veracyte, Inc (VCYT)

Tue, 15 Sep 2026 05:22:00 -0400

Needham analyst Mike Matson reiterated a Buy rating and $69.00 price target on Veracyte, Inc (NASDAQ: VCYT).

The analyst comments "Yesterday, after the close, VCYT announced the acquisition of Convergent Genomics for $150M of upfront cash plus up to $30M in additional milestone payments. Convergent Genomics has developed a tumor-naive minimal residual disease (MRD) assay called UroAmp for non-muscle-invasive bladder cancer (NMIBC) patients. UroAmp is a non-invasive, genomic assay that analyzes 60 urothelial cancer-related genes in a patient's urine, as well as broader changes across a patient's genome. The test has been validated with the RUMBLE study (n=57) which showed

Form 144 VERACYTE, INC. Filed by: Holstein Jens

Mon, 14 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260914/27059155.html

Form 8-K VERACYTE, INC. For: Sep 10

Mon, 14 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260914/27058458.html

Veracyte acquires Convergent Genomics for up to $180M

Mon, 14 Sep 2026 16:05:17 -0400

Veracyte, Inc. (NASDAQ: VCYT) announced the acquisition of Convergent Genomics, adding the UroAmp urinary tumor DNA (utDNA) testing platform to its diagnostics portfolio, according to a company press release dated Sept. 14, 2026.

The deal includes $150 million in upfront cash and up to $30 million in additional cash tied to reimbursement-related milestones. Veracyte said the acquisition's ongoing operating expenses were already reflected in its previously provided 2026 adjusted EBITDA guidance, which the company is not updating.

UroAmp analyzes tumor-derived genomic information from urine samples and has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Mon, 14 Sep 2026 16:05:00 -0400

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its proprietary urinary tumor DNA (utDNA) technology, to Veracyte’s product portfolio. To date, UroAmp has been clinically validated in non-muscle invasive bladder cancer (NMIBC), including therapy-response monitoring and post-treatment surveillance.

In the U.S., there are approximately 85,000 patients diagnosed with bladder

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Mon, 14 Sep 2026 16:05:00 -0400

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

In the U.S., there are approximately 85,000 patients diagnosed with bladder

Form 4 VERACYTE, INC. For: Sep 02 Filed by: Chambers Rebecca

Fri, 11 Sep 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260911/27051760.html

Form 4 VERACYTE, INC. For: Sep 02 Filed by: Febbo Phillip G.

Fri, 11 Sep 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260911/27051780.html

Form 4 VERACYTE, INC. For: Sep 02 Filed by: McGuire Annie

Fri, 11 Sep 2026 11:35:00 -0400

si-local-file:///var/storage/secattach/20260911/27051785.html